Modulation of miR-122 expression affects the interferon response in human hepatoma cells

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 585-590

  Li, Aimei ^a,b   Qian, Jun ^a,b   He, Junming ^a,b   Zhang, Qingmeng ^a,b   Zhai, Aixia ^a,b   Song, Wuqi ^a,c   Li, Yujun ^a,c   Ling, Hong ^a,b   Zhong, Zhaohua ^a,b   Zhang, Fengmin ^a,c  

^a Department of Microbiology ^*  (China)

^b Immunity and Infection Key Laboratory of Heilongjiang Province   (China)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatoma cells; Interferon response; MiR 122

Indexed keywords

HOST FACTOR; INTERFERON; LIPOFECTAMINE; MICRORNA 122;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MODULATION; OLIGODENDROGLIA; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; HEP G2 CELLS; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; LIVER NEOPLASMS; MICRORNAS; OLIGODENDROGLIA; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 84873838963     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1233     Document Type: Article

References (24)

1. Motola Kuba D, Zamora Valdes D, Uribe M and Mendez-Sanchez N: Hepatocellular carcinoma. An overview. Ann Hepatol 5: 16-24, 2006.
2. Okuda K: Primary liver cancers in Japan. Cancer 45: 2663-2669, 1980.
3. Stark GR, Kerr IM, Williams BR, Silverman RH and Schreiber RD: How cells respond to interferons. Annu Rev Biochem 67: 227-264, 1998.
4. Haller O, Kochs G and Weber F: The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344: 119-130, 2006.
5. Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC and Fish EN: Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci USA 100: 13453-13458, 2003.
6. Gresser I and Belardelli F: Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 13: 111-118, 2002.
7. Dunn GP, Bruce AT, Sheehan KC, et al: A critical function for typeI interferons in cancer immunoediting. Nat Immunol 6: 722-729, 2005.
8. Wang L, Tang ZY, Qin LX, et al: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32: 43-48, 2000.
9. Yano H, Ogasawara S, Momosaki S, et al: Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 26: 964-975, 2006.
10. Lin SM, Lin CJ, Hsu CW, et al: Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 100: 376-382, 2004.
11. Qian J, Zhai A, Kao W, et al: Modulation of miR-122 on persistently Borna disease virus infected human oligodendroglial cells. Antiviral Res 87: 249-256, 2010.
12. Jopling CL, Yi M, Lancaster AM, Lemon SM and Sarnow P: Modulation of hepatitis C virus RNA abundance by a liver specific MicroRNA. Science 309: 1577-1581, 2005.
13. Wu X, Wu S, Tong L, et al: miR-122 affects the viability and apoptosis of hepatocellular carcinoma cells. Scand J Gastroenterol 44: 1332-1339, 2009.
14. Coulouarn C, Factor VM, Andersen JB, Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536, 2009.
15. Kirkwood J: Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29 (Suppl 7): 18-26, 2002.
16. Borden EC: Interferons - expanding therapeutic roles. N Engl J Med 326: 1491-1493, 1992.
17. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444-2458, 2000.
18. Wang P, Hou J, Lin L, et al: Inducible microRNA-155 feedback promotes typeI IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 185: 6226-6233, 2010.
19. Hou J, Wang P, Lin L, et al: MicroRNA 146a feedback inhibits RIG I dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 183: 2150-2158, 2009.
20. Liu X, Zhan Z, Xu L, et al: MicroRNA 148/152 impair innate response and antigen presentation of TLR-triggered dendritic cells by targeting CaMKIIα. J Immunol 185: 7244-7251, 2010.
21. Witwer KW, Sisk JM, Gama L and Clements JE: MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J Immunol 184: 2369-2376, 2010.
22. Kutay H, Bai S, Datta J, et al: Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99: 671-678, 2006.
23. Ma L, Liu J, Shen J, et al: Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther 9: 554-561, 2010.
24. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH and Filipowicz W: Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 15: 31-33, 2009.